Biosimilars Market Key Players : 3SBIO Inc., Qilu Pharmaceutical, Novartis International AG (Sandoz International GmBH), Pfizer Inc

The ASEAN and China biosimilars market was valued at $687.6 million in 2017 and is expected to reach $5,506.2 million by 2025 with a CAGR of 29.7% during the forecast period. Biologics experiences rapid growth in the pharmaceutical industry that fuels the development of new treatments for life-threatening and rare illnesses. However, expiry of patents of the biologics that incorporate recombinant technology has been on the rise in recent years. Thus, research-based and generic pharmaceutical companies are pursuing the opportunity to develop "generic" substitutes for original biologics that are known as biosimilars.

The major companies profiled in the report include 3SBIO Inc., Qilu Pharmaceutical, Novartis International AG (Sandoz International GmBH), Pfizer Inc. (Hospira), STADA Arzneimittel, Beijing SL Pharmaceutical Co., Ltd., Fosun Pharmaceutical (Shanghai Fosun Pharmaceutical Co., Ltd.), Amgen Inc., AstraZeneca Plc, and Teva Pharmaceutical Industries Ltd.

Get Sample PDF Brochure : https://www.alliedmarketresearch.com/request-sample/5080

The ASEAN and China biosimilars market is segmented into molecule type, application, and region. Based on molecule type, the market is divided into human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, and peptide. Based on application, the market is classified into blood disorders, oncology diseases, chronic and autoimmune diseases, growth hormone deficiency, and others. Further, the chronic and autoimmune diseases segment is sub-categorized into diabetes, rheumatoid arthritis (RA), glaucoma, and others. Based on region, the market is analyzed across China and ASEAN region.

The key driving factors of the ASEAN and China biosimilars market include rise in the number of blockbuster drugs whose patents would be expiring along with high prevalence of chronic diseases among the ageing population across the ASEAN countries and China. In addition, lower cost of biosimilars drugs than original biologics has fueled the market growth. However, high initial investment in R&D is anticipated to hamper the growth of the market. Moreover, increased focus of the international key players to invest in untapped economies of the ASEAN region and China offers lucrative opportunities for expansion of the biosimilars market.

Application segment review

ASEAN and China biosimilars market constitutes five applications, namely, blood disorders, oncology diseases, chronic and autoimmune diseases, growth hormone deficiency, and others. The chronic and autoimmune diseases segment is further categorized into rheumatoid arthritis (RA), diabetes, glaucoma, and others. The oncology diseases segment generated the highest revenue in 2017 and is anticipated to remain dominant throughout the forecast period. This is attributed to rise in healthcare expenditures owing to expensive drugs used in the treatment of cancer. This has propelled the pharmaceutical manufacturers to invest in the production of cheaper alternatives, i.e. biosimilars. However, the chronic and autoimmune diseases segment is anticipated to grow at the fastest pace during 2018-2025 in the ASEAN and China biosimilars market.

Significant increase in the preference for biosimilars such as human growth hormone and monoclonal antibodies, over branded biologics across the ASEAN countries and China has contributed to the growth of the segment. Increase in the prevalence of glaucoma and diabetes across ASEAN countries and China significantly contributed to the highest CAGR of this segment.

Key Benefits ASEAN and China Biosimilars Market:

• The study provides an in-depth analysis along with the current trends and future estimations of the ASEAN and China biosimilars market to elucidate the imminent investment pockets.
• A comprehensive analysis of the factors that drive and restrict the market growth is provided.
• The quantitative analysis of the industry from 2017 to 2025 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
• An extensive analysis of the key segments of the industry is provided to understand the molecule type and applications of biosimilars across ASEAN countries and China.
• The key players and their strategies are analyzed to understand the competitive outlook of the market.

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David C
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.